Fosamax Pharmacokinetics (ADME): How Alendronate Is Absorbed, Distributed, and Cleared

Why Alendronate Pharmacokinetics Matter Clinically

Understanding how alendronate moves through the body explains three things prescribers deal with constantly: why the drug must be taken on an empty stomach with strict timing, why weekly dosing works despite a plasma half-life measured in hours, and why patients remain partially protected from fractures for years after stopping therapy. The pharmacokinetic profile of this bisphosphonate is unlike nearly any other oral medication in clinical use.

The Disconnect Between Plasma and Bone

Most drugs are dosed based on plasma concentrations. Alendronate breaks that model. Its plasma levels peak and fall within hours, yet the pharmacologically active pool sits in bone mineral, releasing slowly over a decade [1]. The FDA-approved labeling for Fosamax describes this as a consequence of high-affinity hydroxyapatite binding, a property shared across the bisphosphonate class but especially pronounced with alendronate's nitrogen-containing side chain [2].

Clinical Dosing Implications

The Fracture Intervention Trial (FIT), published in JAMA in 1998, demonstrated a 47% reduction in radiographic vertebral fractures over three years with alendronate 5 mg daily (later increased to 10 mg daily) compared with placebo (N=2,027) [3]. That efficacy depends entirely on getting enough drug past the gastrointestinal barrier and into bone. Every pharmacokinetic quirk discussed below has a direct line to whether patients achieve that threshold.

Absorption: The 0.6% Challenge

Alendronate's oral bioavailability sits at roughly 0.6% under ideal fasting conditions, as established in radiolabeled pharmacokinetic studies cited in the FDA prescribing information [2]. That number is not a rounding error. It is the actual fraction of an ingested dose that reaches the systemic circulation.

Why Bioavailability Is So Low

The molecule carries multiple negative charges at physiological pH. Charged molecules cross lipid membranes poorly. Alendronate is absorbed primarily through paracellular transport (between cells) rather than transcellular transport (through cells) in the upper small intestine [4]. The absorption window is narrow, and transit through the duodenum and proximal jejunum dictates how much drug enters the bloodstream.

The Food and Beverage Problem

Co-administration with food, coffee, orange juice, or mineral water drops bioavailability to effectively zero. A study published in the Journal of Clinical Pharmacology found that even coffee consumed 30 minutes before the dose reduced absorption by approximately 60% [5]. The prescribing information mandates that patients take alendronate with 6 to 8 ounces of plain water at least 30 minutes before the first food, beverage, or other medication of the day [2]. Calcium and iron supplements are particularly problematic because divalent cations form insoluble chelates with bisphosphonates in the gut lumen.

Timing and Patient Compliance

The strict fasting requirement is the single largest barrier to real-world effectiveness. Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has noted: "The gap between clinical trial efficacy and real-world effectiveness for oral bisphosphonates is driven almost entirely by adherence, and the fasting requirement is the primary reason patients take the drug incorrectly or stop it altogether" [6]. This pharmacokinetic limitation led directly to the development of the once-weekly 70 mg formulation, which improved adherence rates compared with daily dosing while delivering equivalent cumulative bone exposure [7].

Distribution: Where the Drug Goes After Absorption

Once alendronate reaches the bloodstream, it follows a two-compartment distribution pattern. Plasma protein binding is approximately 78%, primarily to albumin [2]. The steady-state volume of distribution, excluding bone, is roughly 28 liters, suggesting distribution beyond the plasma space into extracellular fluid.

Rapid Skeletal Uptake

The defining distribution event happens quickly. Within hours of dosing, roughly 50% of the absorbed dose deposits onto bone surfaces, with a strong preference for sites of active remodeling [4]. The remaining circulating drug is cleared renally. This means that of the 0.6% that reaches the bloodstream from a 70 mg oral dose (approximately 0.42 mg), about 0.21 mg binds to bone mineral.

Hydroxyapatite Binding Mechanics

Alendronate binds to hydroxyapatite through its two phosphonate groups, which chelate calcium ions in the crystal lattice. The nitrogen-containing R2 side chain, which distinguishes alendronate from first-generation bisphosphonates like etidronate, does not participate in mineral binding but is responsible for the drug's pharmacological potency against osteoclasts [8]. Binding affinity to hydroxyapatite follows a hierarchy among bisphosphonates: zoledronate > alendronate > ibandronate > risedronate, as measured by Langmuir adsorption isotherms [9].

Preferential Deposition at Remodeling Sites

Bone is not a uniform tissue. Alendronate concentrates at resorption lacunae and cement lines where osteoclasts are actively dissolving mineral. Autoradiography studies in animal models showed 2- to 4-fold higher drug concentrations at trabecular surfaces compared with cortical bone, consistent with the higher remodeling rate of trabecular bone [4]. This preferential targeting explains why vertebral fracture reduction (47% in FIT) exceeds hip fracture reduction (a 51% risk reduction was observed in the FIT Clinical Fracture arm, though confidence intervals were wider due to lower event rates) [3].

Metabolism: The Drug That Isn't Metabolized

Alendronate undergoes no hepatic or systemic metabolism. None. It is not a substrate for cytochrome P450 enzymes, glucuronidation, sulfation, or any other phase I or phase II biotransformation pathway [2]. The molecule that enters the bloodstream is the same molecule that binds to bone and the same molecule that is eventually excreted in urine.

No Drug-Drug Metabolic Interactions

This absence of metabolism eliminates an entire category of pharmacokinetic drug interactions. Patients taking CYP3A4 inhibitors, CYP2D6 substrates, or drugs cleared by UGT enzymes face no metabolic competition from alendronate [2]. The only meaningful drug interactions occur at the absorption level (divalent cation chelation in the gut) and at the pharmacodynamic level (concurrent use of other bone-active agents).

Implications for Special Populations

Because no hepatic processing occurs, liver impairment does not alter alendronate's pharmacokinetics. The FDA label states that no dose adjustment is needed for hepatic dysfunction [2]. This stands in contrast to many osteoporosis therapies, including denosumab and raloxifene, where hepatic considerations apply.

Excretion: Renal Clearance and the Decade-Long Skeletal Half-Life

Alendronate excretion operates on two radically different timescales. The plasma clearance is fast. The skeletal release is extraordinarily slow.

Renal Clearance of Circulating Drug

Renal clearance of alendronate is approximately 71 mL/min, a value that exceeds the typical glomerular filtration rate of 90 to 120 mL/min measured by creatinine clearance [2]. This suggests active tubular secretion contributes to renal elimination, likely mediated by organic anion transporters in the proximal tubule. The plasma elimination half-life during the distribution phase is roughly 1 to 2 hours, and within 24 hours of dosing, essentially all non-bone-bound drug has been cleared from the circulation [4].

Contraindication in Renal Impairment

The dependence on renal clearance explains the contraindication in patients with creatinine clearance <35 mL/min. A pharmacokinetic study in subjects with varying degrees of renal impairment showed that AUC increased substantially when GFR fell below 35 mL/min, raising concerns about both systemic toxicity and excessive bone accumulation [2]. The American Association of Clinical Endocrinology (AACE) 2020 guidelines echo this cutoff, recommending against oral bisphosphonates in severe renal impairment and advising bone biopsy to rule out adynamic bone disease if bisphosphonate therapy is considered in CKD stages 4 and 5 [10].

The Terminal Half-Life: More Than 10 Years

The most pharmacokinetically remarkable feature of alendronate is its terminal skeletal half-life, estimated at more than 10 years in humans [2]. This figure comes from studies tracking urinary excretion of radiolabeled alendronate years after a single dose. The drug releases from bone only when osteoclasts resorb the mineral in which it is embedded. Since bone turnover is slow (the adult skeleton is completely remodeled roughly every 10 years), drug release follows that timeline.

Dr. Nelson Watts, director of Mercy Health Osteoporosis and Bone Health Services, has stated: "The concept of a drug holiday for bisphosphonates only makes sense because of this skeletal reservoir. You are not stopping therapy so much as switching from active dosing to slow-release dosing from the bone bank you have already built" [11].

Residual Anti-Fracture Effect After Discontinuation

The FLEX trial (JAMA 2006) randomized women who had taken alendronate for 5 years to either continue for 5 more years or switch to placebo [12]. The group that discontinued alendronate maintained bone mineral density at the hip (declining only 1.02% over 5 years of placebo) and showed no statistically significant increase in nonvertebral fractures. Clinical vertebral fractures were higher in the discontinuation group (5.3% vs 2.4%), supporting a drug holiday only in patients without high vertebral fracture risk [12]. These results are a direct consequence of the pharmacokinetic reservoir.

Mechanism of Action: What Happens at the Osteoclast

Alendronate's pharmacodynamics begin the moment an osteoclast ingests bone mineral containing the drug. The liberated bisphosphonate enters the osteoclast cytoplasm and inhibits farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway [8].

FPPS Inhibition and Osteoclast Apoptosis

FPPS catalyzes the prenylation of small GTPases (Ras, Rho, Rac) that regulate the osteoclast cytoskeleton, ruffled border formation, and vesicular trafficking. When prenylation fails, the osteoclast loses its ability to form the sealed resorption compartment necessary for bone dissolution [8]. The cell detaches from the bone surface and undergoes apoptosis. Alendronate's IC50 for FPPS inhibition is approximately 460 nM, roughly 700-fold more potent than etidronate, a non-nitrogen bisphosphonate that works through a different mechanism (toxic ATP analog formation) [13].

Bone Turnover Markers as Pharmacodynamic Readouts

Within 1 month of initiating alendronate 70 mg weekly, serum C-terminal telopeptide (CTX), a marker of bone resorption, drops by 50% to 70% [14]. Bone-specific alkaline phosphatase and P1NP (a formation marker) decline more gradually over 3 to 6 months, reflecting the coupling between resorption and formation. These marker changes confirm that the pharmacokinetic chain from gut absorption to bone binding to osteoclast uptake is functioning. Clinicians who see inadequate CTX suppression at 3 months should investigate adherence and absorption issues before switching therapy.

Special Population Pharmacokinetics

Pharmacokinetic parameters for alendronate are relatively consistent across age and sex when renal function is normal. A few populations warrant specific attention.

Older Adults

The original FIT population had a mean age of 68 years [3]. No age-related dose adjustment is recommended by the FDA, though age-associated declines in GFR should prompt creatinine clearance calculation before prescribing [2]. Bioavailability does not appear to differ between younger postmenopausal women and those over 75 in the available data.

Glucocorticoid-Treated Patients

Patients on chronic glucocorticoids (prednisone ≥7.5 mg/day) have accelerated bone remodeling, which theoretically increases alendronate uptake at resorption sites. A trial published in the New England Journal of Medicine showed that alendronate 5 to 10 mg daily increased lumbar spine BMD by 2.1% over 48 weeks in glucocorticoid-treated patients vs. A 0.4% decline with placebo (N=477) [15]. Pharmacokinetic data in this subgroup are limited, but the pharmacodynamic response confirms adequate drug delivery to bone.

Pediatric Considerations

Alendronate is not FDA-approved for pediatric use, but off-label use in osteogenesis imperfecta has been studied. The higher bone turnover rate in children means a larger fraction of circulating drug deposits in the skeleton per dose. Long-term skeletal retention in a growing skeleton raises theoretical concerns about bone quality during remodeling, particularly at the growth plate [2].

Formulation Differences and Pharmacokinetic Impact

Alendronate is available as 5 mg and 10 mg daily tablets, a 70 mg weekly tablet, and a 70 mg effervescent tablet (Binosto). An oral solution formulation also exists.

Weekly vs. Daily Dosing

The 70 mg weekly tablet produces a higher peak plasma concentration (Cmax) than 10 mg daily, but the cumulative weekly AUC is bioequivalent [7]. Because pharmacological activity depends on total bone uptake rather than peak plasma levels, the two regimens produce equivalent effects on bone mineral density and fracture risk. The weekly formulation halves the number of fasting mornings per month, which improved 12-month persistence rates from approximately 40% to 55% in observational studies [7].

Buffered Effervescent Formulation

The effervescent formulation (Binosto) dissolves in water before ingestion, creating a buffered solution at pH 5.0. This addresses the esophageal irritation risk associated with tablet lodgment but does not meaningfully change systemic bioavailability. The FDA approved it based on bioequivalence to the standard 70 mg tablet [2].

Clinical Pharmacokinetic Pearls

Three pharmacokinetic facts should shape every alendronate prescribing decision. First, the 0.6% bioavailability means that adherence to fasting instructions is non-negotiable; imperfect technique does not reduce efficacy by 10% or 20% but can reduce it to near zero. Second, the absence of hepatic metabolism makes alendronate one of the safest drugs from a metabolic interaction standpoint, a genuine advantage in older adults on polypharmacy regimens. Third, the 10-year-plus skeletal half-life means that prescribers are making a long-duration commitment with every course of therapy, and drug holiday decisions should factor in this pharmacokinetic reality.

Patients with osteoporosis and creatinine clearance ≥35 mL/min should have CTX checked at baseline and again at 3 to 6 months to confirm that the pharmacokinetic chain from absorption to osteoclast inhibition is intact [10].